Stroma Targeting Nuclear Imaging and Radiopharmaceuticals by Shetty, Dinesh et al.
Hindawi Publishing Corporation
International Journal of Molecular Imaging
Volume 2012, Article ID 817682, 23 pages
doi:10.1155/2012/817682
Review Article
Stroma Targeting Nuclear Imaging and Radiopharmaceuticals
DineshShetty,1,2 Jae-Min Jeong,3 andHyunsukShim1,2
1Department of Radiology and Imaging Sciences, Emory University, 1701 Uppergate Drive, C5008, Atlanta, GA 30322, USA
2Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
3Department of Nuclear Medicine, Seoul National University Hospital, Seoul 110744, Republic of Korea
Correspondence should be addressed to Hyunsuk Shim, hshim@emory.edu
Received 4 January 2012; Accepted 29 February 2012
Academic Editor: Izabela Tworowska
Copyright © 2012 Dinesh Shetty et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Malignant transformation of tumor accompanies profound changes in the normal neighboring tissue, called tumor stroma.
The tumor stroma provides an environment favoring local tumor growth, invasion, and metastatic spreading. Nuclear imaging
(PET/SPECT) measures biochemical and physiologic functions in the human body. In oncology, PET/SPECT is particularly
useful for diﬀerentiating tumors from postsurgical changes or radiation necrosis, distinguishing benign from malignant lesions,
identifying the optimal site for biopsy, staging cancers, and monitoring the response to therapy. Indeed, PET/SPECT is a powerful,
proven diagnostic imaging modality that displays information unobtainable through other anatomical imaging, such as CT
or MRI. When combined with coregistered CT data, [18F]ﬂuorodeoxyglucose ([18F]FDG)-PET is particularly useful. However,
[18F]FDG is not a target-speciﬁc PET tracer. This paper will review the tumor microenvironment targeting oncologic imaging
such as angiogenesis, invasion, hypoxia, growth, and homing, and also therapeutic radiopharmaceuticals to provide a roadmap for
additional applications of tumor imaging and therapy.
1.Introduction
The tumor stroma, consisting of cells, structural proteins,
and signaling molecules, which includes ﬁbroblasts/myoﬁ-
broblasts, glial, epithelial (EC), fat, vascular, smooth muscle,
and immune cells along with the extracellular matrix (ECM)
and extracellular molecules, is playing a central role in
tumor initiation, progression, and metastasis (Figure 1).
Growth factor and chemokine production by ﬁbroblasts and
immune cells is altered, leading to direct stimulation of
tumor cell growth and recruitment of precursor cells, which
themselves respond with abnormal growth and proliferation
[1]. The unique reciprocal act between the various aspects
of the tumor and the microenvironment has been the recent
target of molecular strategies for tumor treatment. Targeting
the stroma poses several obstacles; however, the level of
tumor aggression is greatly inﬂuenced by this environment,
providing multiple targets for anticancer therapy. The cells
associated with stroma are not malignant themselves, which
demands successful therapy to aim at phenotypic changes
unique to this population, while avoiding normal cells
elsewhere. Additionally, malformed tumor vessels contribute
to tumor hypoxia, acidosis, and increased interstitial ﬂuid
pressures which challenge the delivery of target agents to the
stroma. Hence a successful approach requires identiﬁcation
of appropriate targets and eﬃcient delivery methods.
Fibroblasts are the main cellular component of tumor
stroma, comprising an integral component of the tumor.
Fibroblasts are responsible for the deposition of the ﬁbrillar
ECM, which is continually remodeled through a dynamic
process of ECM protein production and degradation
by ﬁbroblast-derived matrix metalloproteinases (MMPs).
Tumor hypoxia inﬂuences cytokines and growth factors such
as Transforming growth factor-beta (TGF-b), stromal cell-
derived factor-1 (SDF-1), matrix metalloproteinase (MMP),
vascular endothelial growth factor (VEGF), and hypoxia-
inducible factor-1 alpha (HIF-1α), which have consistently
been shown to directly impact tumor behavior [2–5]. Tumor
angiogenesis requires active remodeling of existing cells,
which is facilitated by stroma through the expression and
secretion of MMPs. Through the secretion of cytokines,
chemokines,andotherfactors,stromalcellsareinstrumental2 International Journal of Molecular Imaging
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Figure 1: The tumor stromais critical for tumor growth. Malignant transformation is a multistep process involving profound changes in the
normal neighboring tissue, also called tumor stroma. The tumor stroma provides an environment favoring local tumor growth, invasion,
and metastatic spreading.
in creating the unique environment of chronic inﬂammation
and immune tolerance, allowing cancer cells exposure to
growth factors.
The potential high sensitivity and speciﬁcity of nuclear
imaging techniques such as positron emission tomography
(PET) and single photon emission computed tomography
(SPECT) are an attractive option for medical diagnosis.
The high sensitivity of radioisotopes and wide range of
biomolecules which are labeled by these radioactive iso-
topes, such as radioactive halogens (18F, 76Br, 77Br, and
124I), [11C] and radioactive metals (111In, 99mTc, 68Ga,
and 64Cu) made these imaging techniques convenient. In
general, radioactive halogens and carbon are widely used
to label all kinds of radiopharmaceuticals, but mostly for
labeling small molecules, while the radioactive metals are
mainly used for labeling large molecules such as proteins,
peptides, and antibodies by conjugation of metal chelators.
All oncologic imaging tracers are molecularly targeted
radiopharmaceuticals based on the tumor biochemistry such
as increased metabolism, hyperproliferation, angiogenesis,
hypoxia, apoptosis, and speciﬁc tumor biomarkers including
tumor speciﬁc antigens and tumor-speciﬁc receptors. This
paper will review the tumor microenvironment targeting
oncologic imaging and therapeutic radiopharmaceuticals.
We hope to provide a roadmap for additional applications
of tumor imaging and therapeutic agents which could help
researchers and clinicians.
2.Targeting Tumor Angiogenesis
2.1. Integrin-Targeted Nuclear Imaging. Tumor angiogenesis
is an essential mechanism for tumor growth and develop-
ment of metastasis [30, 31]. The angiogenic process depends
on vascular endothelial cell migration and invasion and is
regulatedbycelladhesionreceptors.Membersoftheintegrin
family play important roles in the regulation of cellular
activation, migration, proliferation, survival, and diﬀerenti-
ation [32, 33]. Integrins represent a subclass of cell adhesionInternational Journal of Molecular Imaging 3
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molecules connecting the cytoskeleton with the ECM or
other cells with exposed arginine-glycine-aspartic (RGD)
tripeptide sequence [34–39]. Integrins consist of two geneti-
cally nonrelated subunits, α and β, which are noncovalently
associated with each other [40–42]. Among all, integrin αvβ3
shows overexpression during tumor angiogenesis [30, 43,
44].Integrinαvβ3 ishighlyexpressedonactivatedendothelial
cells but not quiescent endothelial cells of established
vessels [45], making it a suitable target for antiangiogenic
cancer management. Blocking of these interactions with
antagonists leads to detachment of endothelial cells, which
drives apoptosis [35] .T h e r eh a v eb e e nn u m e r o u si m a g i n g
techniques and therapies based on integrin αvβ3 antagonism,
including antibodies, peptides, small molecules, and small
interfering RNA (siRNA) [46]. Since the introduction of the
ﬁrst αvβ3 selective RGD peptides in the 1990s [47, 48], it
has been a lead structure for tracer development [8, 49–
55]. In general design of RGD peptide-based radiotracers,
cyclic RGD peptide serves as the targeting biomolecule
to carry radionuclide to the αvβ3 integrin site (Figure 2).
Various radiolabeled RGD derivatives have been developed
for targeting αvβ3 integrin expressed during angiogenesis
(Figure 3). The pharmacokinetic modifying linker (PKM)
is used to improve the radiotracer excretion kinetics. An
organic synthon is often used for the F-18 labeling, whereas
a multidentate bifunctional chelator (BFC) is used to attach
the metallic radionuclides. For an integrin αvβ3 targeted
radiotracer to be successful, it should have high tumor-
speciﬁc uptake and tumor-to-blood ratios. It should also be
able to distinguish between benign and malignant tumors,
to follow tumor growth and metastasis, and to predict
therapeutic eﬃcacy in integrin αvβ3 positive cancer patients.
The iodinated derivatives of RGD peptide showed
receptor-speciﬁctumoraccumulation,alongwithhighactiv-
ity in the liver due to predominant hepatobiliary excretion
[50].Thesugaraminoconjugate,agalacto-RGDlabeledwith
18F, showed improved pharmacokinetics with signiﬁcant
reductionintheliveraccumulation[6].F orfurtherimpr o v e-
ment of pharmacokinetics, cyclic RGD was conjugated with
tetrapeptides containing hydrophilic D-amino acids [49].
The compounds from this ﬁne tuning approach, speciﬁcally
18F-Asp3-RGD, showed comparable tumor uptake with 18F-
galacto-RGD. This approach brought an alternative for PET
imaging of αvβ3 expression. Another 18F-labeled compound,
cyclo(-Arg-Gly-Asp-D-Phe-MeVal-) which was synthesized
by direct electrophilic ﬂuorination, shows selective integrin-
binding aﬃnity. Even though this tracer showed receptor-
dependent in vivo tumor accumulation, liver and intestine
accumulation is similar to the ﬁrst generation iodinated
compounds. Among the radiotracers evaluated in preclinical
tumor-bearing models, 18F-galacto-RGD [56–59]a n d18F-
AH111585[60,61],thecoresequenceofwhichwasoriginally
discoveredfromaphagedisplaylibrary(asACDRGDCFCG),
are currently under clinical investigation for visualization of
integrin αvβ3 expression in cancer patients.
There have also been several eﬀorts to develop radiomet-
alated analogues of RGD peptides. These peptides were
conjugated with metal chelator at lysine moiety of peptide
and the resulting compounds were labeled with 99mTc,
188Re, 90Y, and recently with 68Ga [7, 54, 62]. The gamma
scintillation images of 99mTc labeled compound showed
clearly contrasting tumor with high tracer uptake in the
kidneys. Van Hagen et al. labeled a DTPA-conjugated cyclo(-
Arg-Gly-Asp-D-Tyr-Lys-) with 111In [55]. Autoradiography
and immunohistochemical results demonstrated receptor-
speciﬁc binding in newly formed vessels. 68Ga-labeled
derivative of cyclic RGD showed signiﬁcant speciﬁc uptake
in tumor xenografted mice (Figure 4). To conﬁrm the
speciﬁc binding of developed tracer, a blocking study was
conducted by injecting cold cyclic RGD before injecting
labeled compound and which demonstrated clear inhibition
of labeled tracer uptake by tumor cells.
To improve the binding aﬃnity, multimeric RGD pep-
tides have been developed. First, cyclic RGD dimers, such
as E [c(RGDfK)]2 were developed as diagnostic (99mTc) and
therapeutic (90Ya n d64Cu) radiotracers [8, 63, 64]. A linear
decapeptidecontainingtwoRGDsiteslabeledwith 99mTchas
been used for human imaging studies [9]. In imaging studies
ofmelanoma,metastaticlesionsexhibitedhightumoruptake
along with high lung and abdomen tracer uptake. Recently,
the 64Cu- and 18F-labeled E [c(RGDyK)]2 were reported as
PET radiotracers [10, 65]. Comparison studies found that
the RGDfE dimer [c(RGDfE)HEG]2-K-Dpr-[18F]FBOA had
much better targeting capability to its monomeric analogue
c(RGDfE)HEG-Dpr-[18F]FBOA[11].Also,manyresearchers
tried to evaluate cyclic RGD tetramers and octamers for
angiogenesis imaging. Most of the results revealed the
enhancement in the binding aﬃnity and internalization due
to peptide multiplicity compared to monomeric or dimeric
analogues [11, 66, 67]. Chen et al. studied 64Cu and 18F
labeled cyclic RGD tetramer and octamer for PET tumor
imaging [68, 69]. Both in vitro assays and ex vivo studies
showed much higher radiotracer uptake in the case of
radiolabeled RGD multimers than their dimeric analogues.
Also, as the peptide multiplicity increases, the uptake of
radiolabeled multimeric RGD peptides in other organs also
signiﬁcantly increased. They also reported the RGD dimers
andtetramersforSPECTimagingoftumorangiogenesis[70,
71]. Even though initial observation credited high binding
aﬃnity to peptide multiplicity, there is need to evaluate the
impact of multivalency on binding.
A quantum-dot- (QD-) based probe was reported
recently for both near-infrared ﬂuorescence (NIRF) and4 International Journal of Molecular Imaging
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PET imaging of integrin αvβ3 expression [72]. In these
studies, cyclic RGD peptides and metal chelators were
conjugated to a QD for imaging of tumors in living mouse
after 64Cu labeling. The combination of PET and NIRF
imaging overcomes the tissue penetration limitation of NIRF
imaging, allowing for quantitative in vivo targeted imaging
in deep tissue. There are also reports on targeting of integrin
αvβ3 positive tumor in mice with 64Cu-labeled single walled
carbon nanotubes (SWNTs) coated with polyethylene glycol
(PEG) chains linked to cyclic RGD peptides [73]. In these
studies, the intrinsic Raman signatures of SWNTs were used
todirectlyprobethepresenceofSWNTsinmousetissuesand
to conﬁrm the radionuclide-based imaging results. Unlike
traditional conjugation methods, in another recent report,
ferritin nanocages were loaded with the RGD peptides
Cy5.5 and 64Cu ferritin for integrin αvβ3 targeted PET/NIRF
imaging [74]. Recently, engineered knottin peptides, which
bind to various integrins with high aﬃnity, were evaluated as
molecular imaging agents [75, 76]. For PET and ﬂuorescence
imaging in a U87MG human glioma model, Cy5.5 or metal
chelator was conjugated to N-terminal of peptide. Results
showed that high aﬃnity knottin peptides had higher tumor
uptake than the low aﬃnity knottin peptides.
For dual-modality imaging with SPECT and ﬂuores-
cence, RGD peptide was labeled with 111In and IRDye800
(LI-CORBiosciences)andevaluatedinintegrinαvβ3 positive
M21 melanoma xenografts [77]. This study demonstrated
the direct comparison of optical and radionuclide imaging
for subcutaneous and orthotopic tumors. In a follow-up
study, the same probe was used for noninvasive detection
of αvβ3-positive tumors in mice [78]. The advantage of
these techniques over other reported methods lies in better
optical imaging resolution and more sensitive detection of
the subcutaneous lesions, while gamma scintigraphy allowed
f o rm o r es e n s i t i v ed e t e c t i o no fd e e p e rs t r u c t u r e s .A c c u r a t e
localizationofPETprobeuptakecanbeverydiﬃcultinsome
cases due to the absence of identiﬁable anatomical structures
even with PET/CT [79, 80]. A combination of PET/MRInternational Journal of Molecular Imaging 5
1 h
2 h
68Ga-NOTA-RGD 68Ga-NOTA-RGD + cold c(RGDyK)
Figure 4: Coronal microPET images of 68Ga-NOTA-RGD in mice
bearing SNU-C4 xenografts with and without cold c(RGDyK)
(60mg). Arrows indicate tumor positions. Acquisition time was
20min [7].
can have the answer for many such drawbacks. Highly
accurate image registration by MRI can aid in PET image
reconstruction. Also, PET/MRI has greatly reduced radiation
exposure compared with PET/CT. As a ﬁrst example to prove
these possibilities, poly(aspartic acid)-coated iron oxide (IO)
nanoparticles (PASP-IO) coupled to cyclic RGD peptides
and metal chelator were reported for integrin αvβ3 targeting
imaging after labeling with 64Cu [81]. PET imaging showed
the highest receptor-speciﬁc in vivo tumor accumulation
of 64Cu-RGD-PASP-IO after 4h after injection, while the
nontargeted particle showed lower tumor uptake. There
are also recent reports on the eﬀort to develop SPECT/CT
dual modeling imaging of tumor angiogenesis by 99mTc-
labeled nanoparticles [82]. It was found that the tumor-
to-muscle signal ratio, after injection of the nanoparticle,
was dose dependent and target speciﬁc. It was quoted that
these nanoparticles can aﬀord highly sensitive and speciﬁc
localization of tumor angiogenesis, which can be further
characterized with high resolution MR neovascular mapping
to predict the responsiveness to antiangiogenic therapies.
VEGF is considered a major angiogenic factor responsi-
ble for the development of the tumor vasculature network.
VEGF-A is the best-characterized member of the VEGF
family and is thought to be the most critical regulator of
the development of the vascular system in various tumors
[83]. Overexpression of VEGF is found in many types of
human tumor, which makes VEGF an attractive target for
antiangiogenic therapy and blocking the signaling of VEGF
in human tumors [84–87]. There have been many reports on
diﬀerent antibodies or chemical molecules binding to VEGF
and its receptors [88].
Currently, the most widely used drug in clinic is beva-
cizumab (Genentech), a humanized monoclonal antibody,
which binds to all VEGF isoforms and thereby blocks the
VEGF-induced endothelial cell proliferation, permeability,
survival, and growth [89, 90]. This drug is approved for
clinical use in metastatic colon carcinoma and non-small-
cell lung cancer [91, 92]. Despite the promising results
of bevacizumab-based therapy, there is a need to monitor
in vivo VEGF downregulation for the selection of the
right patients for bevacizumab-based treatment. To extract
these possibilities, two human anti-VEGF antibodies, VG76e
(an IgG1 mouse monoclonal anti-VEGF antibody) and
HumMV833 (a humanized monoclonal IgG4k antibody),
were tested for noninvasive VEGF imaging [93, 94]. 125I-
and 124I-labeled VG76e, which recognizes the 121, 165,
and 189 isoforms of human VEGF-A, showed speciﬁc
tumor targeting in a human ﬁbrosarcoma xenograft model.
Maximum uptake was seen after 24h and declined at 48h
after injection. PET studies in various solid tumors using
124I-HuMV833, which binds to VEGF121 and VEGF165,
showed variable tumor uptake within patients [94]. These
diﬀerences are possibly due to the variations in available
targets for the antibody between tumor types. There are also
reports on bevacizumab labeling with the long-lived PET
isotope 89Zr and the single γ-emitting isotope 111In [95–97].
In contrast to the result observed for labeled antibody
VG76e, 89Zr-bevacizumab has not shown tumor clearance
upto168hafterinjection,whichindicatestheslowclearance
of bevacizumab, thus inappropriate as a diagnostic imaging
probe. In an alternative approach, Cai et al. reported VEGF-
receptor imaging in a human glioma bearing mouse model
with 64Cu-DOTA-VEGF121 [98]. In vivo VEGF receptor
imaging could facilitate the evaluation of VEGF-receptor
expression, whereas radiolabeled bevacizumab could be used
to evaluate VEGF levels. In the subsequent study, researchers
showed the feasibility of 89Zr-bevacizumab for microPET
and CT imaging with enabled quantitative measurement
of the tracer in the tumor [99]. There was an interesting
report on imaging of liver metastasis in colorectal cancer
patients with 111In-labeled bevacizumab [100]. These studies
revealed an enhanced uptake in the liver metastases in 9 of
the 12 patients. But the level of antibody accumulation in
tumor lesions varied considerably. There was no correlation
found between the level of tracer accumulation and the
level of VEGF-A expression in the tissue. Recently there has
also been a report on 64Cu-labeled bevacizumab for PET
imaging of VEGF expression in colorectal cancer xenografts,
which showed signiﬁcant correlation of tumor accumula-
tion of 64Cu-DOTA-bevacizumab with VEGF expression as
measured by western blot analysis [101]. This study showed
higher tumor uptake than the previous report by Nagengast
et al., which allowed serial scans due to the longer half-life
of the isotope [99]. Even though there are no conclusions on
VEGF imaging or therapy, all these exciting reports warrant
eﬀorts to learn about new and novel tracers for anti-VEGF
therapy.
2.2. Integrin-Targeted Radiotherapy. Integrin αvβ3 targeted
radionuclidetherapyoftumorsusingmonoclonalantibodies
(mAbs) and RGD peptides was also investigated by diﬀerent
research groups. Delivery vehicles such as antibodies, RGD6 International Journal of Molecular Imaging
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Figure 5: Coronal microPET images and radioactivity accumulation quantiﬁcation of nude mice bearing U87MG tumors (treated with
[90Y]-Abegrin, [90Y]-IgG, Abegrin, or saline) after i.v. injection of [18F]FDG (a) and [18F]ﬂuoro-L-thymidine (b).
peptides, and other small molecules have been investigated
for integrin-targeted delivery of cytotoxic drugs and gene
inhibitors [46]. The strategy to speciﬁcally target multiple
sites of disease through radioimmunotherapy minimizes the
normal tissue toxicity, which causes cell death of adjacent
tumor cells. Researchers tried to eliminate the inevitable
production of human anti-murine immunoglobulin anti-
bodies (HAMA) after one to three treatments in patients
by utilizing chimeric mAbs or complete humanization of
the protein [102]. Though there are several other factors
limiting treatment, including slow blood clearance, high
uptakeinnormalorgans,andinsuﬃcienttumorpenetration,
there are few studies using antibody for integrin-targeted
therapy in progress. To overcome these problems, there has
been a new strategy in development of smaller constructs,
such as antibody fragments and subfragments, which are
capable of binding to the tumor while clearing from normal
tissues rapidly [102]. Recently, there was a promising report
on therapeutic potential of 90Y-labeled humanized anti-
integrin αvβ3 monoclonal antibody (90Y-Abegrin), which
was evaluated in U87MG glioma xenograft models [103].
Imaging studies revealed a reduction of cell proliferation,
metabolic activity, and DNA synthesis in the 90Y-Abegrin-
targeted group (Figure 5).
Low-molecular-weight peptides show fast blood clear-
ance and rapid tumor penetration in contrast to monoclonal
antibodies.Eventhoughinrecentyearsstructurallymodiﬁed
RGD peptides and analogues were used as the integrin αvβ3-
targeting vehicles, there are very few reports on therapeutic
tumor targeting. One such report on radiolabeled dimeric
RGD peptide E [c(RGDfK)]2 showed signiﬁcant increased
survival in the case of 90Y-DOTA-E [c(RGDfK)]2-injected
mice compared to untreated mice in an ovarian cancer
mouse model [8], but follow-up study failed to attain
therapeutic eﬃcacy by increasing the number of injections
[104]. There are also reports on 90Y-labeled tetrameric RGD
peptides for integrin αvβ3-targeted internal radiotherapy in
mousetumorxenografts.Also,onemorereportsuggeststhat
the pharmacokinetically improved RGD dimers with PEG4
and Gly3 linkers labeled with 90Y showed signiﬁcant anti-
tumor vasculature eﬀects for integrin αvβ3-positive tumors
[105]. In another report, the tumor therapeutic potential of
90Y/111In-labeled monomeric RGD peptide was evaluated in
a human ovarian cancer xenograft, and it was claimed that
the RGD monomer can be used for fractionated therapy
without major toxicity. But due to the lower tumor uptake
of the RGD monomer, multiple-dose administration was
necessary to achieve therapeutic eﬃcacy [106]. Recently,
177Lulabeledtwoknottinpeptides(2.5Dand2.5F),andRGD
peptides targeting a range of integrins (αvβ3/αvβ5/α5β)w e r e
testedforpotentialradiotherapyinamousemodelofhuman
glioma [107, 108]. 177Lu-DOTA-2.5F showed much better
in vivo results in integrin-positive tumors as a radionuclide
therapeutic agent.
Integrin-targeted radiotherapy by nonpeptide antago-
nists has also been reported. DOTA-conjugated nonpeptide
integrin αvβ3 antagonist (TA138) was labeled with 90Y
and 177Lu and tested in an adenocarcinoma model [109].
Biodistribution studies showed similar tumor uptake for
both 111In-TA138 and 90Y-TA138. Results demonstrated a
slowing of tumor growth and a regression of tumors.
Theranostics for cancer therapy using radiolabeled pep-
tide derivatives has been attempted recently [110, 111].
For example, octreotide derivatives were used for imagingInternational Journal of Molecular Imaging 7
neuroendocrine tumor patients after labeling with 68Ga
or 111In, and then were administered for therapy after
labeling with 90Yo r177Lu clinically [112–115]. However,
clinical results of RGD or knottin labeled with therapeutic
radionuclides have not been reported yet.
3.Targeting Tumor Invasion
3.1. MMP. The matrix metalloproteinase family shares
speciﬁc functional and structural components necessary for
extracellular secretion and activation of the enzyme. MMP
family members are classiﬁed on the basis of additional
protein domains such as hemopexin or a ﬁbronectin-like
region that contribute to their individual characteristics
[116]. During active tissue remodeling, MMPs are rapidly
transcribed, secreted, and activated [117]. Tumor-associated
MMP expression and activity includes a major contribution
of surrounding stromal cells. In epithelial cancers, most of
the upregulated MMPs are expressed by the host stromal
cells [118]. MMPs can also be expressed by tumor cells.
MMP7 is commonly expressed in adenocarcinomas, and
several MMPs are expressed in the malignant epithelium of
tumors that have undergone an epithelial-to-mesenchymal
transformation [119]. MMP expression is upregulated in
malignantcancerscomparedtonormal,benign,orpremalig-
nant tissues [120–122]. MMPs are often associated with the
removal of the ECM barrier to allow cancer cells to invade
and metastasize [123]. These enzymes are secreted and
activated in the extracellular environment, avoiding the need
to transfer the probe to intracellular compartments, which
is a great advantage when considering MMP as a molecular
target. Compared to the probes binding to targets in a 1:1
fashion, there is an advantage of signal ampliﬁcation due to
MMP’s catalytic activity at physiological pH. Even though
MMPswereconsideredattractivetargetsforthedevelopment
of anticancer drugs, much attention was directed to the
design and synthesis of MMP inhibitors (MMPis) with the
ﬁrst clinical result reported in the 1990s [124]. Since MMPis
aredesignedtorecognizetheactivesiteofMMPs,thebinding
of radiolabeled MMPis thus serves as an activity-based probe
for MMP activity in vivo. So designing the compound to
recognize distinct features of the active site of individual
MMP family members gives an excellent selectivity.
Initial attempts to develop radiolabeled MMPis have
shown unsuccessful in vivo results. Labeled potent MMPis
such as [11C]MSMA and [11C]CGS25966 showed high levels
of nonspeciﬁc binding in mouse models of breast cancer
[125]. Evaluation of [11C]FMAME, a molecule developed
by the same group, concluded nonspeciﬁc binding [126].
[18F]SAV03, another MMPi labeled with 18F along with its
methyl ester derivative, [18F]SAV03M, which is used as a
prodrug, showed signiﬁcantly higher uptake in tumor tissue
than other organs in biodistribution studies [127]. The
tumoraccumulationofradioactivityobservedinwholebody
autoradiographywith[18F]SAV03Mpromisedthepossibility
of using this agent for visualizing tumors by PET. The
radioiodinatedMMPis 123I-and[125I]125I-CGS27023A, 123I-
and 125I-HO-CGS 27023A by Kopka et al. showed good
in vitro aﬃnities towards MMP2 and MMP9 [128]. They
observed rapid blood and plasma clearance of the 125I-
labeled CGS compounds which supports the concept of
utilizing these radiotracers for imaging MMP activity [129].
T h e r eh a v ea l s ob e e nr e p o r t so nl a b e l e dt r y p t o p h a n -a n d
valine-based biphenylsulphonamide MMPis, which showed
eﬀective inhibition and selectivity for MMP2 [130, 131].
But in vivo results failed the expectations, with poor tumor
uptake in nude mice bearing A549 lung tumors.
RecentlytherewasareportonMarimastat,anoncovalent
MMPi labeled with 18F. In the reported method, shelf-stable
arylboronicestersconjugatewasusedasacaptorforaqueous
18F ﬂuoride in a novel method. Developed tracer was
localized to the tumors [132]. Despite a relatively low signal-
to-noise ratio indicated by PET imaging, tumor labeling was
speciﬁc to target. This report is important mainly because of
novel labeling methodology rather than in vivo application
of labeled MMPis. There are also reports on usage of
99mTc-labeled broad-spectrum MMPi, RP-805, to evaluate
correlation of macrophage apoptosis and MMP release in
vivo [133]. Atherosclerosis was produced in rabbits receiving
a high cholesterol diet (HC), who underwent radionuclide
imaging. MMPi uptake was best visualized in HC diet
animals and reduced signiﬁcantly after ﬂuvastatin treatment
or diet withdrawal. There was a signiﬁcant correlation
between 99mTc-MMPi and 111In-Annexin A5 (AA5) uptake;
both correlated with pathologically veriﬁed MMP-9 activity
and macrophage content. It should be noted that several
studies using 18F-conjugated MMPis for in vivo imaging also
revealed high uptake of tracer in tissues with known MMP
overexpression such as the liver and blood [127, 134]. This is
a particular problem for broad-spectrum MMPis and leads
to poor target/nontarget contrasts when imaging diseased
tissues.Withmoredatabecomingavailableontheexpression
and activity of speciﬁc MMPs in particular pathologies, anti-
bodies, or small molecule inhibitors with narrow speciﬁcity
can be developed as future molecules [132]. There have been
reports of using endogenous inhibitors of MMPs, the tissue-
speciﬁc inhibitors of matrix-metalloproteinases (TIMPs). A
clinical SPECT imaging study on ﬁve patients with Kaposi’s
sarcoma (KS) using N-TIMP-2-DTPA labeled with 111In was
disappointing in that none of the patients showed signiﬁcant
uptake in KS lesions [135].
3.2.uPAR. Urokinase-typeplasminogenactivator(uPA)and
its cell-surface receptor (uPAR) are central molecules for
cell surfaces-associated plasminogen activation [136, 137].
The uPA/uPAR system has an important role in cancer
progressionandmetastasis[138].uPAisaglycosylatedserine
protease that catalyzes the conversion of plasminogen to
plasmin. Binding of pro-uPA to uPAR (CD87) results in
proteolytic activation [136, 139]. Binding of uPA to uPAR
serves to focalize uPA activity to facilitate invasion of uPAR
expressing cancers by activation of a proteolytic cascade that
breaks down extracellular matrix components and allows
cancer cell migration into vasculature and lymphatics [136].
Also, the uPA/uPAR system is involved in regulating cell-
extracellular matrix interactions by acting as an adhesion
receptor for vitronectin and by modulating integrin function8 International Journal of Molecular Imaging
[139]. These properties of the uPA/uPAR system attracted
researchers to use it as a cancer therapeutic target [137].
Li et al. demonstrated the noninvasive imaging of uPAR
expression in a living subject for the ﬁrst time by using a
small linear peptide (D-Cha-F-s-r-Y-L-W-S) (AE105) with
high aﬃnity for human uPAR in uPAR xenotransplanted
mouse tumor models after labeling with the positron emitter
64Cu [140]. In vivo PET imaging analysis in high levels of
uPAR expressing U87MG glioma cells and uPAR-negative
MDA-MB-435 breast cancer cells revealed gradual increase
of 64Cu-DOTA-AE105 uptake in U87MG tumors with time
and uptake that remained close to background in the
case of MDA-MB-435 tumors. To conﬁrm the receptor
speciﬁcity, the author studied the imaging of 64Cu-DOTA-
AE105mut (AE105mut, D-Cha-F-s-r-Y-L-E-S) in U87MG
tumor-bearing mice. The aromatic side chain residue of the
tryptophan residue in AE105 is indispensable for the high-
binding aﬃnity toward uPAR as reported previously [136,
141]. The glutamate replacement in this residue was accom-
panied by only minimal uptake in U87 tumor. Although the
speciﬁcity in targeting uPAR with the 64Cu-DOTA-AE105 is
proven in this study, it is not clear whether this radiotracer
actually would allow a quantitative measurement of receptor
expression in vivo. Also, the liver uptake of 64Cu-DOTA-
AE105 is relatively high, which may limit its applicability
to measure lesions in the liver and intestines. Therefore
this promising study needs to improve the pharmacokinet-
ics of this radiopharmaceutical. The author suggested the
possibility of using a soluble pseudosymmetrical dimer of
AE105 displaying a higher aﬃnity for uPAR and increased
solubility [141]. It has been shown that uPA-uPAR binding
is species speciﬁc with little cross-reactivity between human
andmurineproteins[142].Asimilarselectivitywasobserved
in the case of AE105 as revealed by binding studies using
surface plasmon resonance. Hence PET imaging studies of
xenotransplanted human tumors in mice used in this study
are most unlikely to bind mouse uPAR expressed by the
tumor-associatedmurinestromaandvasculaturecells.There
was also a report on usage of a dimeric peptide most
closely related to peptide antagonist (D-X-F-s-r-Y-L-W-S-
G)2-β-A-K (AE120), modiﬁed by the addition of DOTA C-
terminal to a branching lysine residue [141]. Kn¨ or et al.
subsequently used it in an in vivo model of human ovarian
cancer and demonstrated tumor uptake of the 213Bi complex
of 2.2% (0.4% ID/g at 90min after injection) [143]. But the
speciﬁcity of tumor uptake of the 213Bi-labeled peptide in
vivo was not addressed.
In a subsequent study, Liu et al. synthesized and charac-
terizedasmallpeptideinhibitoroftheuPA-uPARinteraction
and modiﬁed it to contain a C-terminal DOTA chelating
moiety for labeling with 111In to obtain (NAc-dD-CHA-
F-dS-dR-Y-L-W-S-Ala)2-K-K([111In]-DOTA) [144]. The in
vivobiodistribution comparison proﬁle to that of 125I-amino
terminal fragment (ATF) in mice bearing MDA-MB-231
humanbreastcancerxenograftshowedsigniﬁcantlydiﬀerent
data at all time points examined. At 1 and 4h post injection,
bloodlevelsofeachradiotracerweredistinctlydiﬀerent,with
the higher molecular weight ATF fragment demonstrating
signiﬁcantly slower clearance. 125I-ATF uptake was higher in
all normal tissues at these time points, with the exception of
liver and kidney, which demonstrated higher levels of 111In-
peptide. Increased liver and kidney retention was observed
for the 111In-labeled branched peptide relative to 125I-ATF
at 24h. The tumor uptake value shown by this peptide was
similar to Kn¨ or et al. [143], although the values are not
directly comparable due to diﬀerences in the model system,
radioisotope, and experimental protocol.
4.Targeting Tumor Hypoxia
Hypoxia can occur due to structural abnormalities of
microvessels and the limited diﬀusion distance (<70mm) of
oxygen within the tumor. Increase in tumor aggressiveness
and metastatic potential of solid tumors is believed to
be highly associated with the presence of hypoxia within
the cancer [145]. Tumors often adapt to hypoxic environ-
ments by upregulation of the HIF-1, a heterodimer protein
composed of oxygen-sensitive HIF-1α and constitutively
expressed HIF-1β subunits. When stabilized by hypoxic
conditions, HIF-1 binds and transactivates several genes
associated with enhanced glycolysis and angiogenesis. Due
to these changes, patients with hypoxic tumors often have
a poor prognosis and decreased overall survival rate due to
higher degrees of invasiveness and resistance to chemo- and
radiation therapy [146–148]. These limitations drive signiﬁ-
cant importance to the need to detect hypoxia within tumors
for cancer management. Currently, the eppendorf needle
electrodesystemhasbeenusedforthedirectmeasurementof
oxygen level in tumors, which is limited only to easily acces-
sible tumors. There are limitations in direct measurement
of hypoxia because they are invasive procedures and may be
subject to sampling error; additionally, it is diﬃcult to reach
all tissue sites, and thus measurements are only accessible
at the time of surgery. Because of the heterogeneous nature
of hypoxia in tumors, substantial interest has been paid
to the development of noninvasive techniques that permit
serial noninvasive imaging of hypoxia, which could extract
valuable information on disease that is required in oncology
applications.
For the hypoxia detection, the tracer should be speciﬁc
for hypoxia, its uptake should reﬂect clinically relevant
cellular pO2 values (0–10mmHg) irrespective of the tumor
type and grade, and it should easily cross the blood
capillary membrane, preferably without using membrane
transporter systems, which otherwise might complicate the
interpretation of imaging results. Thus, rapid membrane
permeation and localization to the viable hypoxic target
tissue with high speciﬁcity is essential. Although none of
the currently available tracers have all the properties of
an ideal hypoxia imaging agent, the selection is based
largely on tumor type, ease of synthesis, and availability
of radioisotope. 2-Nitroimidazole, which is reduced under
hypoxic conditions and consequently accumulates in sites of
h y p o x i a ,h a sb e e na na t t r a c t i v em o l e c u l ef o rm a n yy e a r sf o r
PET or SPECT imaging purposes after labeling with diﬀerent
radioisotopes [15, 148, 149]. Under hypoxic conditions,
the nitroimidazole molecule undergoes an enzymatic single
electron reduction, depending on the availability of oxygen,International Journal of Molecular Imaging 9
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Figure 6: Schematic representation of the proposed mechanism for the binding of nitroimidazole radiotracers in hypoxic environment.
which forms a radical anion (Figure 6). The process is
initiated byanenzyme-mediated singleelectronreductionto
form a free radical. The rate of oxidation is dependent on the
intracellular concentration of oxygen. In hypoxic tissue, the
reduced compound is not able to be oxidized; instead, it is
further reduced and binds to intracellular components.
Detection of tumor hypoxia with radionuclides was ﬁrst
demonstrated with [14C]-misonidazole by autoradiography
[150], which was later proposed for noninvasive PET imag-
ing of tumor hypoxia after labeling with 18F. Since then,
several other tracers which include [18F]ﬂuoroerythronitro-
imidazole (FETNIM), [18F]ﬂuoroazomycin arabinoside
([18F]FAZA), 123I-iodoazomycin arabinoside ([123I]IAZA),
64/62/60Cu-diacetyl-bis(4N-methylthiosemicarbazone)(64Cu-
ATSM), 99mTc-butylene amineoxime (99mTc-HL91), and 2-
(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[18F]pentaﬂuoro-
propyl) acetamide ([18F]EF5) have been evaluated for this
purpose (Figure 7).
18F-misonidazole ([18F]FMISO) has been used for PET
imaging quantiﬁcation of hypoxia in a variety of tumors,
including head and neck cancer, non-small-cell lung cancer,
breast cancer, and brain tumors [16] .T h e s es t u d i e sh a v e
shown tumor-to-background ratio of at least 0.88–5.85 after
2 to 3h after injection. One major limitation of this tracer
is slow clearance from nonhypoxic tissues. [18F]FAZA was
developed to undergo more rapid clearance from blood and
nontarget tissues than [18F]FMISO [13]. Because of these
improved imaging properties, [18F]FAZA is recommended
for further preclinical and clinical study for imaging tumor
hypoxia in various tumors including lymphoma and gliomas
[151]. Compared with [18F]FMISO, [18F]FAZA displays
a higher tumor-to-background ratio (1.2 to 15.5). Also,
the signiﬁcantly lower tumor-to-blood ratio resulting from
[18F]FAZA is related to either renal or hepatobiliary excre-
tion, leading to a lower radiation burden and to a favorable
imaging result compared with [18F]FMISO [13]. In patients
with glioblastoma multiforme, [18F]FAZA yielded high
tumor-to-background ratios duetoselectiveandpresumably
hypoxia-speciﬁc uptake in tumors reﬂecting blood-brain-
barrier disruption. It has been reported that [18F]FAZA PET
can be used to deﬁne the target volume for dose increase in
radiation treatment planning [152]. Even though [18F]FAZA
shows signiﬁcant promise for hypoxia imaging, there is no
direct comparison with [18F]FMISO in patients. [18F]EF5
is one of the most liphophilic 2-nitroimidazole derivatives
developed for hypoxia imaging. The lipophilicity of the
compound was enhanced by introducing ﬁve ﬂuorine atoms
to the nitroimidazole side chain, which could also increase
its biological half-life. This tracer has unique advantages,
including its use as a ﬂuorescence immunohistochemistry
marker for hypoxia in nonradioactive form. Also, its high in
vivo stability is an additional advantage. In the case of both
[18F]FAZA and [18F]EF5, the time required after injection
to obtain good images is 2 to 3h. The ﬁrst human study
of [18F]EF5 showed hypoxia-speciﬁc tumor binding in head
and neck cancer [153].
64Cu-ATSM is a nonnitroimidazole compound devel-
oped for hypoxia imaging [18]. The use of copper-labeled
radiopharmaceuticals for PET is attractive because of the
increasing availability of four positron-emitting radionu-
clides of copper, such as 60Cu (t1/2 = 0.40h, β+ = 93%,
EC=7%), 61Cu (t1/2 = 3.32h, β+ = 62%, EC = 38%),
62Cu (t1/2 =0.16h, β+ = 98%, EC = 2%), and 64Cu (t1/2 =
12.7h, β+ =17.4%, EC=43%) [154]. 62Cu can be produced
by generator (62Zn/62Cu generator) system [155, 156],
whereas 60Cu, 61Cu, and 64Cu are produced by cyclotron
[157, 158] using reliable and reproducible targets. In a
hypoxic environment, Cu(II)-ATSM can be trapped intra-
cellularly after the one-electron reduction, which resulted
in Cu(I)-ATSM. It shows high tumor-to-background ratios
(1.0 to 10.4) in less than 1h after injection with rapid
delineation of tumor hypoxia. It has been shown to be
selective for hypoxic cancers and ischemic myocardial tissue
[159]. A comparative biodistribution study in mice bear-
ing EMT6 tumors with 64Cu-ATSM, 64Cu-pyruvaldehyde-
bis(N4-methylthiosemicarbazone) (PTSM), and 18F-MISO
showed optimal tumor uptake of both agents after 10min
after injection, suggesting a rapid trapping mechanism for
these agents in solid tumors [160]. Ex vivo autoradiography
of tumor slices after coinjection of 64Cu-ATSM and 64Cu-
PTSM into the same animal was also studied. The results
showed uniform spreading of 64Cu-PTSM throughout the
EMT6 tumor compared to heterogeneous uptake of 64Cu-
ATSM, suggesting that 64Cu-ATSM has better selectivity for
hypoxia imaging. Clinical studies have shown that 60Cu-
ATSM can predict tumor response to therapy in diﬀerent
types of cancers [161]. A direct comparison of 60Cu-ATSM
and 64Cu-ATSM scans in cervical cancer patients showed
similar patterns and magnitudes of uptake, but 64Cu-ATSM
produced better-quality images than 60Cu-ATSM due to low
noise [162].10 International Journal of Molecular Imaging
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However, the production of these radiotracers is limited
to cyclotron systems, which are expensive as well as diﬃcult
to handle. Other than the cyclotron produced radioisotopes,
an alternative method to label biomolecules is the use of
68Ga, which can be obtained from a commercially available
radionuclide generator system [7, 163–168]. 68Ga is an
economical alternative to the cyclotron produced radionu-
clides. Compounds characterized by high hydrophilicity
were thought to be better for imaging hypoxia because of
rapid blood clearance and high target-to-nontarget ratio.
Recently, 68Ga-labeled nitroimidazole (NI) analogues were
developed [19, 20] for PET hypoxia imaging (Figure 8).
These derivatives showed elevated uptake in hypoxic condi-
tions compared to normoxic conditions in both in vitro and
in vivo studies.
5.Targeting Tumor Growthand
Recruitment/Homing
5.1. Receptor Tyrosine Kinase. Because of the importance
of the epidermal growth factor receptor (EGFR) signaling
pathway in malignant progression of various types of
tumors [169], there has been growing interest in the use
of EGFR-TK inhibitors as probes for molecular imaging of
EGFR overexpressing tumors via PET/SPECT [170–172].
Such noninvasive and repetitive monitoring of the activity of
EGFR at the kinase level could provide a direct measure of
EGFR occupancy and inhibition by EGFR-targeting drugs.
These observations led several research groups to develop
novel radiolabeled EGFR-kinase-speciﬁc agents for SPECT
and PET imaging. Most of these agents are derivatives of
quinazolines that reversibly or irreversibly bind to the EGFR
ATP-binding pocket (Figure 9). Noted agents include a
reversible 4-[(3,4-dichloro-6-[18F]ﬂuorophenyl)amino]-
6,7-dimethoxyquinazoline (ML01), which was tested
in an EGFR overexpressing subcutaneous tumor [21].
In another study, the biodistribution of [11C]-labeled
4-(3-bromoanilino)-6,7-dimethoxyquinazoline ([O-11C-
methyl]PD153035) has been evaluated in rat neuroblastoma
xenografts [22]. Both these studies concluded that, because
of the reversibility of binding to EGFR, these radiotracers
were rapidly washed out of tumor tissue without generating12 International Journal of Molecular Imaging
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an adequate target-to-background ratio. To improve
the radiotracer retention at the EGFR kinase site, a
N-4-[(4,5-dichloro-2-ﬂuorophenyl)amino]quinazolin-6-yl-
[11C]acrylamide ([11C]ML03) was developed [23]. Despite
some improvement in tumor targeting, the very short
half-life of 11C (20min) limits opportunity for imaging.
With these studies, the authors concluded that eﬀective
EGFR imaging agents based on inhibitors that irreversibly
bind only to the active form of EGFR kinase labeled with
longer-lived radionuclides are required to allow for suﬃcientInternational Journal of Molecular Imaging 13
washout of nonspeciﬁc radioactivity and development of
higher signal-to-background ratios. Due to limitations of
reversible inhibitors as imaging agents, researchers shifted
their focus towards the design and development of novel
irreversible inhibitors as imaging candidates [23, 170].
Inhibitors like [4-(3-iodoanilino)-quinazolin-6-yl]-am-
ide-(3-morpholin-4-yl-propyl)-amide (ML04) [22]a n d4 -
dimethylamino-but-2-enoic acid [4-(phenylamino)-quin-
azoline-6-yl]-amide [24] reported better pharmacologic
proﬁles than previously studied irreversible inhibitors
[23]. The biodistribution of 18F-ML04 was evaluated in
nude mice bearing human glioma xenografts, U87MG-
wtEGFR [24]. After 3h after injection, tracer activity
in the tumor was 2–7-fold higher than other organs.
Although the in vivo pharmacology and stability of ML04
was much better than other reported irreversible radio-
labeled EGFR kinase inhibitors, PET images in tumor-
bearing animal models remained suboptimal. Ineﬃcient
formation of covalent adducts with EGFR kinase domain
could be the reason for these observations. The interac-
tionsof[4-(3-[124I]iodoanilino)-quinazolin-6-yl]-amide-(3-
morpholin-4-yl-propyl)-amide, the morpholino-124IPQA to
the ATP-binding site of activated EGFR and covalent adduct
were also analyzed. Studies conﬁrmed that the extension
of a side chain from the 6-position of [4-(3-halogeno-
anilino)-quinazoline] pharmacophore does not signiﬁcantly
impact the EGFR kinase inhibitory activity of this class
of compounds. There are also promising studies on PET
imaging using the morpholino-[124I]-IPQA in rats bearing
dual tumor xenografts [171]. However, despite the lower
lipophilicity of morpholino-[124I]-IPQA, it still exhibited a
signiﬁcant hepatobiliary clearance. Towards the further opti-
mization of aminophenyl-quinazoline-based agents, Dissoki
et al. had reported several analogues of quinazoline with
short polyethylene glycol (PEG) side chains (Figure 9)[ 25].
These derivatives were labeled with 18F at the terminal
positions of the PEG chain. Labeled compounds showed a
decreased potency of inhibition along with increased length
ofPEGsidechain.Also,studiesrevealedthebetterpossibility
of PEGylated ML04 derivatives for molecular imaging of
EGFR-positive tumors than ML04.
Levashova et al. reported dEGF (a Cys-tagged dimeric
EGF)-based SPECT tracer prepared by direct radiolabeling
of Cys-tag with 99mTc, while the corresponding PET tracers
were prepared by conjugating a PEGylated DOTA chelator
to Cys-tag, followed by radiolabeling with 64Cu [173]. PET
tracers were evaluated in a luciferase-positive MDA-MB-
231 breast tumor and observed clear accumulation in large
(10–15mm) size tumor at 3h after injection. Also, SPECT
tracers were tested in breast carcinoma and spontaneous
mouse lung carcinoma models [174, 175]. In both models,
the tracers showed signiﬁcant accumulation in the tumors.
More recently there has been a report on radiohalogenated
4-anilinoquinazoline-based EGFR-TK inhibitors as potential
cancer imaging agents [176]. In vitro results showed micro-
molar inhibition of EGFR autophosphorylation and EGFR
expressing cell proliferation. But poor 18F labeling yield of
the most eﬀective compound in this series hampered further
biological evaluation.
5.2. Somatostatin Receptors. Somatostatin is a regulatory
peptide and its action is mediated by membrane-bound
receptors (SSTRs), G-protein-coupled receptors, that are
highly expressed in many diﬀerent types of human tumors,
notably neuroendocrine tumors (NET) [177], which in
clinical practice are usually carcinomas and pheochromo-
cytomas. SSTRs are also expressed, to variable extents, in
renal cell carcinoma, small cell lung cancer, breast cancer,
prostate cancer, and in malignant lymphoma [163]. There
are ﬁve SSTR subtypes, but subtype 2 (SSTR2), subtype 5
(SSTR5), and to a lesser extent, subtype 3 (SSTR3) have
higher aﬃnities than SSTR1 and 4, and thus, commercially
available synthetic somatostatin analogues target these three
high aﬃnity receptors [178] .T h e s ea n a l o g u e sa r er e q u i r e d
because somatostatin is rapidly degraded by enzymes in
vivo, as reﬂected by its short biological half-life, and thus,
agents with high aﬃnity for SSTR have been developed
which are resistant to enzyme degradation. Somatostatin
analogues, such as DOTA-TOC, show better images than
111In-DTPA-octreotide, the most commonly used somato-
statin analogue [179]. The phenylalanine residue at position
3 was replaced by tyrosine in DOTA-TOC, which makes the
compound more hydrophilic, increases aﬃnity for SSTR2,
and increases uptake by SSTR2-positive tumors [180]. Other
peptides have also been linked to DOTA, such as DOTA-
octreotate, which has high aﬃnity for SSTR2 [178], and
DOTA-lanreotide, which has high aﬃnity for SSTR5. DOTA-
NOC is the newest addition to these compounds and has
high aﬃnity for SSTR2, SSTR3, and SSTR5. Furthermore,
these DOTA-peptide products show high radiochemical
purity, rapid renal clearance, and high accumulation in
tumors, and overall represent remarkable advances over
standard peptides [181]. Antunes et al. demonstrated that
gallium 67Ga- and 68Ga-DOTA-octapeptides have distinctly
better preclinical pharmacological performance than 111In-
labeled peptides, especially on SSTR2-expressing cells and
in animal models [163]. In particular, 68Ga-DFO-octreotide
injected into rats bearing SSTR-positive pancreatic tumors
demonstrated selective binding to tumor sites with a tumor
to background ratio of 5 [182]. Subsequently, several DOTA-
SST analogues were evaluated in vivo,a n d68Ga-DOTA-TOC
and 68Ga-DOTA-NOC were found to be the most promising
[183–186]. Radiotherapy with 111In-labeled somatostatin
analogues was attempted, but only occasional objective
tumor responses were observed [187, 188]. Also, using the
high energy beta emitter 90Y, labeled with DOTA-[Tyr3]-
octreotide, partial tumor remission was achieved [189, 190].
The improved therapeutic eﬃcacy was achieved by 177Lu-
labeled [DOTA,Tyr3,Thr8]-octreotide, which has higher
aﬃnity for sstr2 than [DOTA,Tyr3]-octreotide [191, 192].
68Ga-based PET tracers (68Ga-DOTATOC, 68Ga-
DOTATATE, and 68Ga-DOTANOC) are widely used, in
which 68Ga-DOTANOC has aﬃnity for sst2, sst3, and
sst5, resulting in a better diagnostic sensitivity than 68Ga-
DOTATATE, which has the highest sst2 aﬃnity [193].
Studies comparing the 68Ga-based peptides with 111In-
labeled octreotide showed the PET images with distinctly
higher sensitivity [194]. Most recently, several phase I and
II clinical studies on targeted radionuclide therapy using14 International Journal of Molecular Imaging
diﬀerent combinations have been reported [195, 196].
The variability in the therapeutic injected dose, number
of treatment cycles, and recruited patients population
makes the comparison of these data very complex. The
90Y-labeled DOTA-lanreotide was investigated in 39 patients,
but no objective response was noticed [197]. Clinical data
on 90Y-DOTATATE show an objective response rate of
37% [198]. Other clinical studies using 90Y-DOTATOC
in 60 patients resulted in 23% objective response rate
[199]. They also report on 177Lu-DOTATATE therapy in
35 patients initially and in follow-up studies with 310
patients, which shows around 30% objective response rate
[200, 201]. Recently, a very exciting combination therapy
approach was studied using 90Y-DOTATATE in tandem
with 90Y/177Lu-DOTATATE. The therapy with tandem
radioisotopes provided longer overall survival than with
a single radioisotope and the safety of both methods was
comparable [202]. Eﬀorts are continuing to improve the
therapeutic eﬃcacy of somatostatin derivatives labeled with
therapeutic radionuclides.
5.3. Chemokine Receptor. The chemokine receptors, which
belong to a family of seven transmembrane domain G-
protein-coupled receptors, consist of 18 members [203].
Numerous studies have reported that CXCR4 among all
chemokine receptors plays a critical role in tumor invasion
and metastasis by interacting with its ligand stromal cell-
d e r i v e df a c t o r - 1( S D F - 1o rC X C L 1 2 ) ,w h i c hi sh i g h l y
expressed in common destination organ sites of metastasis
[204, 205]. The CXCR4/SDF-1 interaction and the resulting
cell signaling cascade have emerged as highly relevant targets
since they play pleiotropic roles in metastatic progression,
especially homing. CXCR4 is overexpressed in more than
20 diﬀerent human cancers [206, 207], and therefore has
been proposed as a prognostic factor and therapeutic target
[208, 209]. In initial attempts to image CXCR4 expression in
cancer models, researchers evaluated 111In-labeled peptides
and 125I-labeled monoclonal antibodies with SPECT/CT
[210, 211]. Hanaoka et al. designed a 14-residue peptide
inhibitor, Ac-TZ14011 and evaluated it in nude mice
bearing the CXCR4-expressing pancreatic carcinoma AsPC-
1, after labeling with 111In [210]. Results showed greater
accumulation of radioactivity in the tumor than in the
blood or muscle. The authors found that conjugation with
diethylenetriaminepentaacetic acid (DTPA) and labeling
with 111In reduced the speciﬁcity of the analog to CXCR4
by 6-fold. Another group of researchers opted to label the
endogenous ligand for CXCR4, SDF-1α with 99mTc, for
quantitation of CXCR4 expression in myocardial infarction.
These ﬁndings revealed 5-fold higher levels of CXCR4 in
infarcted myocardium subjected to ischemic injury than
noninfarcted areas at 24h after injury. 99mTc-labled SDF-
1α showed high aﬃnity and speciﬁcity for its endogenous
chemokine receptor [212]. CXCR4 also proved to have
an important role in brain tumor development, growth,
and metastasis. To evaluate CXCR4 expression in U87MG
xenografts, researchers generated a radiolabeled version of
a mouse antihuman CXCR4 antibody (12G5) and imaging
was conducted using SPECT/CT [211]. In imaging and
biodistribution studies, highest uptake was seen in the
spleen, followed by the tumor. The tumor-derived cells
showed a 2- to 7-fold increase in surface CXCR4 expression
in ﬂow cytometry results, which indicates the signiﬁcant
retention of radioactivity observed in larger tumors due
to 125I-12G5 binding to CXCR4 and not by enhanced
permeability and retention. These results demonstrate the
feasibility of imaging tumor microenvironment induced
CXCR4 expression, to provide an indirect readout on the
heterogeneity of tumors.
Recently, Nimmagadda et al. imaged CXCR4 expression
in two human breast cancer cell lines with 64Cu-labeled
CXCR4 inhibitor AMD3100 (Figure 10)[ 26]. However,
the author attributed high liver and background tissue
uptake to basal levels of CXCR4 expression and moderate
plasma protein binding (58%) observed with AMD3100.
Additionally, the bicyclam AMD3100 has a relatively low
aﬃnity (∼651 ± 37nM) and a structurally restricted
scaﬀold. The same group pursued their research with
monocyclam analog N-[1,4,8,11-tetraazacyclotetradecanyl-
1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine
(AMD3465) to image CXCR4 expression (Figure 10)
[27]. Compared with AMD3100, AMD3465 has higher
aﬃnity, reduced size, and charge [213]. AMD3465 was
shown to be 10-fold more eﬀective as a CXCR4 antagonist
than the bicyclam AMD3100 [214]. The speciﬁcity, target
selectivity, and tumor-to-muscle ratios observed suggest
that 64Cu-AMD3465 is a better agent for in vivo PET,
compared with other known agents. Imaging studies clearly
demonstrated selective accumulation of radioactivity in
the CXCR4-positive U87MG tumors. The tumor-to-muscle
and tumor-to-blood ratios for 64Cu-AMD3465 at 90min
after injection were 7- to 8-fold higher than those of 64Cu-
AMD3100. Even though 64Cu-AMD3465 has improved
aﬃnity and kinetics, considerable uptake in the liver and
kidneys remains a concern.
There are also recent reports on labeling of CXCR4 pep-
tide antagonist T140 (Figure 10)w i t h18F and its evaluation
in vivo as a CXCR4 imaging agent [28]. Results show that,
when injected in high speciﬁc activity (with no addition of
unlabeled mass of peptide), 18F-T140 bound to mouse RBCs
and gave high background signal. But binding to the RBCs
was blocked by coinjection of the tracer, also resulting in
elevated accumulation in CXCR4 positive tumor. Apart from
these drawbacks, radiosynthesis of 18F-T140 requires several
steps, a long reaction time and results in low yield, limiting
its potential for clinical use. The same group of researchers
simpliﬁed the synthesis of T140-based tracer by conjuga-
tion of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid mono (N-hydroxysuccinimide ester) (DOTA-NHS)
and labeled with 64Cu to generate 64Cu-T140-2D deriva-
tive (Figure 10)[ 29]. Even though radiosynthesis is sim-
pliﬁed, 64Cu-T140-2D showed similar behavior as 18F-
T140 in terms of binding to mouse RBCs and human
RBCs. Also, signiﬁcantly higher uptake in the kidney and
liver over time compared to 18F-T140 remains a concern.
The same studies with 68Ga labeling ended with simi-
lar results. All these ﬁndings reveal the need of addi-
tional considerations to develop successful CXCR4 imagingInternational Journal of Molecular Imaging 15
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Figure 10: Structures of radiotracers developed for imaging CXCR4 expression in tumors. 64Cu-labeled small molecule CXCR4 inhibitors
(64Cu-AMD3100 and 64Cu-AMD3465) [26, 27]a n d18F-labeled peptide inhibitors (18F-T140 and 18F/M-T140-2D) [28, 29].
agents. Most recently Gourni et al. evaluated the 68Ga-
labeled high-aﬃnity cyclic CXCR4 ligand, 68Ga-CPCR4-
2 (cyclo(DTyr1-[NMe]-D-Orn2-[4-(aminomethyl) benzoic
acid,68Ga-DOTA]-Arg3-2-Nal4-Gly5)) [215].Labeledligand
showed high in vivo stability with high and speciﬁc tumor
accumulation, which was reduced by approximately 80% in
competition studies with AMD3100.
6. Summary
Molecular imaging will play a key role in shaping 21st
century cancer management. Cooperative eﬀorts are needed
from biologists, chemists, engineers, medical physicists, and
mathematicians in identifying, synthesizing, and charac-
terizing excellent imaging probes and in developing high
sensitivity imaging instruments. The probes developed for
tumorangiogenesisimagingcanalsohavebroadapplications
for other angiogenesis-related diseases, such as myocardial
infarction, stroke, atherosclerosis, chronic inﬂammation,
and others. Even though there is still room for improvement,
the diagnostic and radiotherapeutic targeting of neuroen-
docrine tumors with peptide-based nuclear probes has been
proven very useful. The development of new radiopeptides
with improved pharmacokinetics could help to explore the
full potential of targeted radiation therapy. The investigation
of integrin αvβ3 targeted delivery of radiopharmaceuticals
is relatively rare and further research eﬀort is still needed
to develop novel integrin-targeted radiotherapy with better
tumor targeting eﬃcacy and desirable pharmacokinetics.
There is yet to be a clear winner in the approaches used to
image in vivo M M Pa c t i v i t y .T h e r ea r es e v e r a lt e c h n o l o g i c a l
advances that are likely to make important contributions to
the development of MMP-based imaging agents. Although
the search for an ideal hypoxia imaging agent is likely to
continue, current PET hypoxia imaging methods already
show promise for hypoxia-directed treatments. Even though
targetingthetyrosinekinasedomainoftheEGFRfortherapy16 International Journal of Molecular Imaging
and noninvasive molecular imaging in vivo has been in the
focus for more than a decade, obtaining a desirable probe
remains a challenge. Despite all the challenges and draw-
backs, tumor stroma remained as the most desirable target
for molecular imaging and therapy for cancer management,
asnewtargetslike CXCR4anduPA/uPARsystemsaregetting
additional interest.
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